A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Phase of Trial: Phase III
Latest Information Update: 29 May 2019
Price : $35 *
At a glance
- Drugs Decitabine (Primary) ; Hydroxycarbamide
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- 05 Dec 2018 Planned End Date changed from 1 Oct 2019 to 1 Dec 2020.
- 05 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated